Pancreatic Cancer Research

ResearcherUniversity of CincinnatiActive in the last 2 years

Olugbenga Olanrele Olowokure

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5008163883, A5111504192. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 1, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2012: 1 trial · 2013: 1 paper · 2014: 2 papers · 2015: 4 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 15

  1. Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19990-7↗
  2. ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20039-y↗
  3. Radiation therapy in borderline resectable pancreatic cancer: A review. Co-author DOI 10.1016/j.surg.2021.12.013↗
  4. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? Co-author DOI 10.1245/s10434-022-11363-0↗
  5. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.1245/s10434-022-11580-7↗
  6. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment. Co-author DOI 10.1016/j.jss.2020.09.009↗
  7. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.05.013↗
  8. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Can… Co-author DOI 10.1097/mpa.0000000000001602↗
  9. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv264↗
  10. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv477↗
  11. Simultaneous presentation of pancreatic cancer in a genetically unrelated couple. First author DOI 10.1136/bcr-2014-207760↗
  12. Pulmonary metastases in pancreatic cancer, is there a survival influence? Last author DOI 10.3978/j.issn.2078-6891.2014.114↗
  13. Impact of diabetes mellitus on the outcome of pancreatic cancer. Last author DOI 10.1371/journal.pone.0098511↗
  14. Pancreatic cancer: current standards, working towards a new therapeutic approach. Co-author DOI 10.1586/14737140.2014.895937↗
  15. Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC). Co-author DOI 10.3978/j.issn.2078-6891.2013.013↗

Trials 1

  1. Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer Principal investigator NCT01693276↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan R. Kharofa · 7 shared papers, 2020–2026 · strength 1.21
  2. Sameer H. Patel · 7 shared papers, 2020–2026 · strength 1.21
  3. Davendra P. S. Sohal · 5 shared papers, 2022–2026 · strength 0.97
  4. Gregory C. Wilson · 5 shared papers, 2022–2026 · strength 0.97
  5. Syed Ameen Ahmad · 6 shared papers, 2020–2022 · strength 0.79
  6. Ryan P. Johnson · 2 shared papers, 2026 · strength 0.53
  7. Syed A. Ahmad · 2 shared papers, 2026 · strength 0.53
  8. Paul H. McClelland · 2 shared papers, 2026 · strength 0.53
  9. Kevin M. Turner · 3 shared papers, 2022 · strength 0.44
  10. Xiaoyang Qi · 2 shared papers, 2014–2020 · strength 0.19
  11. Leah K. Winer · 1 shared paper, 2021 · strength 0.14
  12. Mahender Yellu · 1 shared paper, 2015 · strength 0.11
  13. Michelle F. Barrord · 1 shared paper, 2020 · strength 0.11
  14. Kombo F. N’Guessan · 1 shared paper, 2020 · strength 0.11
  15. Harold W. Davis · 1 shared paper, 2020 · strength 0.11
  16. Clayton S. Lewis · 1 shared paper, 2020 · strength 0.11
  17. Zhengtao Chu · 1 shared paper, 2020 · strength 0.11
  18. Jen Jen Yeh · 1 shared paper, 2020 · strength 0.11
  19. Vladimir Y. Bogdanov · 1 shared paper, 2020 · strength 0.11
  20. Michelle Mierzwa · 1 shared trial, 2012 · strength 0.10
  21. Ayham Deeb · 1 shared paper, 2015 · strength 0.08
  22. Deirdre Jill Cohen · 2 shared papers, 2015 · strength 0.07
  23. Bert H. O’Neil · 2 shared papers, 2015 · strength 0.07
  24. Antonio Jimeno · 2 shared papers, 2015 · strength 0.07
  25. Mike Cusnir · 2 shared papers, 2015 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.